La recherche de la beauté et de la santé sont des éléments essentiels pour de nombreuses personnes. Pour y parvenir, orientez-vous vers des compléments alimentaires capables de répondre aux besoins sp ...

Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th ...

LONDON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that it will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Monday ...

Interested parties may access the live webcast of the presentation by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replay will be ...

To schedule a 1on1 investor meeting with Valneva, institutional investors and analysts can contact Valneva’s investor relations department at [email protected].

To access the patient portal, navigate to buckinghampsychiatry.com, then click the “Patient Portal” link at the top right corner of the home page. In order to access the portal’s features, patients ...

About LB Pharmaceuticals LB Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia. The ...

By integrating Predictive Oncology’s AI-driven small molecule solid tumor expertise with Renovaro’s AI-powered liquid biopsy and cancer vaccine programs, we envision an opportunity to provide patients ...

Arcutis is providing this information in accordance with Nasdaq Listing Rule 5635 (c) (4).

As previously announced, ACELYRIN held an End of Phase 2 (EOP2) meeting with the United States Food and Drug Administration (FDA) in Q3 2024 and gained alignment on the proposed LONGITUDE-1 and ...

Pour rencontrer Valneva, les investisseurs institutionnels et les analystes peuvent contacter le service Relations investisseurs de Valneva à l’adresse [email protected].

Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock.